leisure time -WSS

leisure time

author：explore 2025-10-01 02:14:43 - browse：52232

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： NIH study of ME/CFS points to clear biological hallmarks

WSS

Readout Newsletter: Merck, J&J, and long Covid

The Harvard botanist who searched for psychedelics in the Amazon

New brain studies show LSD's effects on the brain in full color

STAT readers on older presidents, polypills, Medicare, and more

Community Health Systems hospitals under DOJ investigation

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

entertainment

leisure time

Bluebird and the case for gene therapy profits

leisure time

In age of alternative facts, a scholarly course on calling out crap

STAT readers on older presidents, polypills, Medicare, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

The high cost of giving birth even with insurance

In utero gene editing: an explainer

Jerome Adams on the need for new antivirals for Covid

Humana cuts profit projections as Medicare Advantage costs soar

Apple is now the first public company to be valued at $3 trillion

Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Medicare inequities exacerbate Puerto Rico’s health disparities

FDA clears AI tool for detecting skin cancer

Prior authorization will have to move faster under new Biden rule

Biotech venture capitalists face new demands from investors

Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

hotspot

Wikipedia

focus